title: Five-year experience with a triple drug protocol in renal transplantation.
authors.affiliation: Department of Nephrology, Hospital Universitario La Fe, Valencia, Spain.
authors.forename: L M
authors.initials: LM
authors.lastname: Pallardó
authors.forename: J
authors.initials: J
authors.lastname: Sánchez
authors.forename: J
authors.initials: J
authors.lastname: García
authors.forename: N
authors.initials: N
authors.lastname: Puig
authors.forename: P
authors.initials: P
authors.lastname: Sánchez
authors.forename: J L
authors.initials: JL
authors.lastname: Górriz
authors.forename: J M
authors.initials: JM
authors.lastname: Cruz
mesh_terms: D000704:Analysis of Variance; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001803:Blood Transfusion; D016572:Cyclosporine / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008775:Methylprednisolone / Q000627:therapeutic use*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D011241:Prednisone; D008775:Methylprednisolone